

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EDDING GENOR GROUP HOLDINGS LIMITED

亿腾嘉和医药集团有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

**VOLUNTARY ANNOUNCEMENT
IND APPROVAL FROM THE NMPA FOR PHASE II
CLINICAL TRIAL OF GB268 IN COLORECTAL CANCER**

This announcement is made by Edding Genor Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Group about the latest business advancement of the Group. References are made to the announcements of the Company dated 2 July and 6 August 2026 in relation to the progress of GB268.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the investigational new drug application (the “**IND**”) for a Phase II clinical trial of GB268, the Company’s highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific antibody, in combination with chemotherapy as first-line treatment for locally advanced or metastatic colorectal adenocarcinoma that is not amenable to curative surgical resection or local therapy, was approved by the China National Medical Products Administration (the “**NMPA**”) on 9 October 2026. This milestone marks preliminary regulatory recognition of the clinical development plan for GB268 and lays a solid foundation for the Company to advance the clinical trial.

The indication covered by the IND approval is advanced colorectal cancer, including locally advanced colorectal cancer that is not amenable to curative treatment and metastatic colorectal cancer. Mismatch repair-proficient/microsatellite-stable (“**pMMR/MSS**”) tumours account for approximately 95% of this patient population and are widely recognised as insensitive to immunotherapy monotherapy, while improvements in the efficacy of conventional chemotherapy and targeted therapies have plateaued. There is therefore an urgent clinical need for new treatment strategies that improve efficacy, prolong survival and have manageable toxicity, so as to improve survival outcomes for patients with pMMR/MSS advanced

colorectal cancer. Through the fine-tuned modulation of its PD-1, CTLA-4 and VEGF arms, GB268 improves the tumour immune microenvironment, promotes T-cell infiltration and inhibits angiogenesis. It has shown the potential to overcome the immune barrier in pMMR/MSS advanced colorectal cancer, and its combination with chemotherapy has the potential to reshape the first-line treatment landscape for pMMR/MSS advanced colorectal cancer.

About GB268

GB268 received NMPA approval for a first-in-human clinical trial in July 2025. Preliminary data from the 10 mg/kg to 30 mg/kg dose cohorts of the Phase I monotherapy study demonstrated favourable safety and tolerability, encouraging PK/PD profiles and anti-tumour activity across all dose cohorts. The relevant clinical data are expected to be presented at the European Society for Medical Oncology (“**ESMO**”) annual meeting in October 2026.

In June 2026, GB268 received approval from the NMPA for a Phase Ib/II clinical trial for the treatment of locally advanced unresectable or metastatic breast cancer, including triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer, to explore monotherapy, immunotherapy in combination with chemotherapy and immunotherapy in combination with antibody-drug conjugates. The first subject dosing was successfully completed on 5 August 2026. GB268 is expected to undergo Phase II clinical studies as monotherapy or in combination therapy in multiple solid tumours, including but not limited to advanced breast cancer, non-small cell lung cancer, colorectal cancer, biliary tract cancer and other solid tumours.

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 11 October 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.